DEALS
Zhong Lun Assists with the Establishment and RMB 950 Million Series A Financing of Doma Biopharma
Zhong Lun Assists with the Establishment and RMB 950 Million Series A Financing of Doma Biopharma
Doma Biopharmaceutical (Suzhou) Co., Ltd. ("Doma Biopharma") recently announced its completion of Series A financing of RMB 950 million, which was jointly provided by Biocytogen, China Life Private Equity, PICC Capital, SDIC Venture Capital, Suzhou Industrial Park, Taiping Innovation and CMB International.
Doma Biopharma was established in September 2021 at BioBAY, Suzhou. After the financing, the company will, by tapping into powerful open technology R&D platforms and strong capital strength of its shareholders, create a "fully integrated innovation incubation platform for life sciences" with Chinese characteristics in the fields of innovative drugs and cutting-edge biotechnologies. Doma Biopharma dedicates itself to incubating biotechnology companies with inventive vitality, developing avant-garde drug pipelines and biotechnologies with independent intellectual property rights, and building innovative life sciences industry clusters.
Zhong Lun has provided full legal services for the entire process of the establishment and Series A financing of Doma Biopharma. Partner Ying (Julia) Zhu was the project leader, and non-equity partner Yinzi (Ted) Hu was the lead lawyer. The team also included Ruoyao (Coco) Ma and other associates.
